FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W151291288> ?p ?o ?g. }

• W151291288 endingPage "32" @default.
• W151291288 startingPage "323" @default.
• W151291288 abstract "Despite improvements seen in median and overall survival using a combination of platinum-compounds and paclitaxel (PTX), long-term survival rates for patients with advanced epithelial ovarian carcinoma remain disappointing and ongoing efforts have aimed to develop more effective primary therapy. In the early 1990Os the drug PTX was first tested in ovarian cancer. In the Gynaecological Oncology Group (GOG) trial 111 the cisplatin (CP)+PTX regimen was judged to be superior compared to the platinum-based control arm with an improvement of overall response rate, median progression-free interval and overall median survival. These favourable data were confirmed by a European-Canadian Intergroup trial (OV10). In contrast, in a further GOG trial (GOG132) there was no difference in survival between CP alone and the combination of PTX and CP. The International Collaborative Ovarian Neoplasm Study (ICON)3 is the first and only trial comparing PTX plus carboplatin against carboplatin alone or a (non-taxane) CP-based control arm. The last analysis performed with a total of 1,293 events showed an estimated absolute difference in one-year progression-free survival of 1% and in two-year overall survival of 2% both in favour of PTX plus carboplatin. The results of ICON3, in accordance with GOG132 study, appear to contradict the earlier positive results seen for PTX and CP in the GOG-111 and OV10 trials and suggested that single agent carboplatin, CY-adriamycin-CP are safe and effective first-line treatments for women requiring chemotherapy for ovarian cancer. A meta-analysis with individual patient data is warranted to better clarify the issue of PTX in the front line therapy of advanced ovarian cancer. Salvage chemotherapy is often utilised in patients with advanced ovarian cancer, due to the high frequency of recurrent disease even after a clinical or pathological complete response after primary chemotherapy. Main objectives of salvage chemotherapy include: i. improvement in quality of life and symptoms; ii. tumour load reduction and survival advantage; iii. evaluation of potentially active new drugs to be included in first-line. Since the goal is palliation in most cases, monotherapy is generally indicated. However, the chances of response are directly related to the treatment-free interval, with a response rate nearly equivalent to that of primary chemotherapy when the treatment-free interval exceeds 24 months. Extension of the platinum-free interval before re-treatment with platinum or taxanes may allow partial reversal of resistance to these agents which can therefore still show significant activity in relapsing patients. Unfortunately, durable response to salvage chemotherapy is rare and cure is almost impossible. The sequential use of the agents currently available for salvage treatment in monotherapy may transform ovarian cancer into a chronic disease and confers long survival to the patients. Perhaps, the most interesting role of second-line chemotherapy is to identify new potentially active drugs, which can be moved up-front. Most of the compounds used in second line (gemcitabine, topotecan, liposomal doxorubicin) are in fact under investigation to develop alternative schedules and sequences of drug administration. A new phase III multi-national randomised study for patients with advanced stage epithelial ovarian or primary periperitoneal carcinoma will evaluate the impact of incorporating a new drug within either a platinum-based triplet (new drug + platinum + PTX) or a sequential-doublet (new drug + platinum followed by platinum + PTX) in order to identify one or more experimental regimens able to improve long-term survival with acceptable toxicity." @default.
• W151291288 created "2016-06-24" @default.
• W151291288 creator A5029489211 @default.
• W151291288 creator A5032167897 @default.
• W151291288 creator A5039754432 @default.
• W151291288 creator A5070972279 @default.
• W151291288 creator A5076377266 @default.
• W151291288 creator A5076421182 @default.
• W151291288 date "2001-09-06" @default.
• W151291288 modified "2023-09-23" @default.
• W151291288 title "Medical therapy of advanced malignant epithelial tumours of the ovary." @default.
• W151291288 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11535983" @default.
• W151291288 hasPublicationYear "2001" @default.
• W151291288 type Work @default.
• W151291288 sameAs 151291288 @default.
• W151291288 citedByCount "2" @default.
• W151291288 countsByYear W1512912882012 @default.
• W151291288 crossrefType "journal-article" @default.
• W151291288 hasAuthorship W151291288A5029489211 @default.
• W151291288 hasAuthorship W151291288A5032167897 @default.
• W151291288 hasAuthorship W151291288A5039754432 @default.
• W151291288 hasAuthorship W151291288A5070972279 @default.
• W151291288 hasAuthorship W151291288A5076377266 @default.
• W151291288 hasAuthorship W151291288A5076421182 @default.
• W151291288 hasConcept C121608353 @default.
• W151291288 hasConcept C126322002 @default.
• W151291288 hasConcept C143998085 @default.
• W151291288 hasConcept C2776694085 @default.
• W151291288 hasConcept C2777292972 @default.
• W151291288 hasConcept C2777511904 @default.
• W151291288 hasConcept C2778239845 @default.
• W151291288 hasConcept C2780258809 @default.
• W151291288 hasConcept C2780427987 @default.
• W151291288 hasConcept C2780739268 @default.
• W151291288 hasConcept C2781413609 @default.
• W151291288 hasConcept C2781451048 @default.
• W151291288 hasConcept C3019054536 @default.
• W151291288 hasConcept C530470458 @default.
• W151291288 hasConcept C535046627 @default.
• W151291288 hasConcept C71924100 @default.
• W151291288 hasConceptScore W151291288C121608353 @default.
• W151291288 hasConceptScore W151291288C126322002 @default.
• W151291288 hasConceptScore W151291288C143998085 @default.
• W151291288 hasConceptScore W151291288C2776694085 @default.
• W151291288 hasConceptScore W151291288C2777292972 @default.
• W151291288 hasConceptScore W151291288C2777511904 @default.
• W151291288 hasConceptScore W151291288C2778239845 @default.
• W151291288 hasConceptScore W151291288C2780258809 @default.
• W151291288 hasConceptScore W151291288C2780427987 @default.
• W151291288 hasConceptScore W151291288C2780739268 @default.
• W151291288 hasConceptScore W151291288C2781413609 @default.
• W151291288 hasConceptScore W151291288C2781451048 @default.
• W151291288 hasConceptScore W151291288C3019054536 @default.
• W151291288 hasConceptScore W151291288C530470458 @default.
• W151291288 hasConceptScore W151291288C535046627 @default.
• W151291288 hasConceptScore W151291288C71924100 @default.
• W151291288 hasIssue "4" @default.
• W151291288 hasLocation W1512912881 @default.
• W151291288 hasOpenAccess W151291288 @default.
• W151291288 hasPrimaryLocation W1512912881 @default.
• W151291288 hasRelatedWork W151291288 @default.
• W151291288 hasRelatedWork W1986000387 @default.
• W151291288 hasRelatedWork W2025352271 @default.
• W151291288 hasRelatedWork W2031554341 @default.
• W151291288 hasRelatedWork W2060767396 @default.
• W151291288 hasRelatedWork W2109576506 @default.
• W151291288 hasRelatedWork W2253817994 @default.
• W151291288 hasRelatedWork W2400212447 @default.
• W151291288 hasRelatedWork W2410995755 @default.
• W151291288 hasRelatedWork W4230339874 @default.
• W151291288 hasVolume "10" @default.
• W151291288 isParatext "false" @default.
• W151291288 isRetracted "false" @default.
• W151291288 magId "151291288" @default.
• W151291288 workType "article" @default.